OPRX Earnings & Financial Statements
OptimizeRx Corporation
$8.29
-$0.14(-1.60%)
61
Overall
60
Value
58
Tech
65
Quality
Market Cap
$156.15M
Volume
81.52K
52W Range
$4.54 - $22.25
Target Price
$12.60
OPRX earnings and financial statements: OptimizeRx Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
OPRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $109.43M | $92.13M | $71.52M | $62.45M | $61.29M |
| Cost of revenue | $35.83M | $32.75M | $28.62M | $23.48M | $25.65M |
| Operating income | $11.69M | -$13.71M | -$26.40M | -$12.29M | $361.1K |
| EBITDA | $17.68M | -$8.06M | -$21.10M | -$7.01M | $2.45M |
| Net income | $5.13M | -$20.11M | -$17.57M | -$11.44M | $378.1K |
| EPS (diluted) | $0.27 | $-1.10 | $-1.03 | $-0.64 | $0.02 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $176.92M | $171.17M | $183.37M | $134.65M | $140.99M |
| Total liabilities | $48.62M | $54.17M | $56.82M | $8.54M | $9.61M |
| Shareholders’ equity | $128.29M | $117.00M | $126.55M | $126.11M | $131.38M |
| Cash and equivalents | $23.36M | $13.38M | $13.85M | $18.21M | $84.68M |
| Long-term debt | $21.66M | $31.02M | $34.60M | $144.5K | $236.7K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $18.71M | $4.89M | -$7.24M | $10.65M | $726.0K |
| Capital expenditure | -$58.0K | -$112.0K | -$871.0K | -$244.6K | -$486.0K |
| Free cash flow | $18.66M | $4.78M | -$8.11M | $10.41M | $240.0K |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OPRX | $8.29 | -1.6% | 81.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |